Cephalon Provides Update Related To Final NUVIGIL(TM) Labeling

Fri, 08 Dec 2006 02:00 PM EST

... Cephalon, Inc. (Nasdaq: CEPH) announced today that the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) has informed the company that it is continuing to evaluate the single case of serious rash reported in a SPARLON(TM) (modafinil) Tablets [C-IV] clinical study. [click link for full article] ...